An 18-percentage-point survival gap at three years is the number that makes the MajesTEC-3 data worth examining closely. At 34.5 months of median follow-up, 83.3% of patients receiving teclistamab plus daratumumab were alive at the 36-month mark, against 65.0% for those on investigator’s choice of standard daratumumab-based regimens. That gap, in a population with only one to three prior lines of therapy, is the strategic argument for moving a BCMA-targeting bispecific earlier in the treatment sequence.
The trial compares the combination against established daratumumab doublets, including regimens the FDA has already approved in this same patient population. Daratumumab with carfilzomib and dexamethasone, for instance, received approval in August 2020 for patients with one to three prior lines. Adding teclistamab to a daratumumab backbone, rather than replacing it, is a deliberate design choice: it lets the trial sit within a familiar standard-of-care frame while testing whether BCMA engagement on top of CD38 blockade changes the survival trajectory materially. The 34.5-month follow-up suggests it does.
The model-based analysis released today goes beyond the observed survival curve to project long-term outcomes, estimating that more than 85% of teclistamab-plus-daratumumab patients remain alive at a horizon beyond the trial’s current data maturity. Extrapolation models carry inherent assumptions, and the confidence intervals around those projections matter as much as the point estimates. What the observed data can support without modeling is the 36-month OS rate itself, and that figure is durable enough to carry weight in a regulatory or payer conversation. Teclistamab as a monotherapy received FDA accelerated approval in October 2022 for patients with at least four prior lines, making the earlier-line MajesTEC-3 setting a meaningful expansion of the potential label.
The number to track from here is whether the observed OS advantage holds as the MajesTEC-3 data matures toward its prespecified final analysis, because the gap between a model-projected benefit and a confirmed one is exactly where regulatory decisions get complicated.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
